Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Peipp, Matthias  [Clear All Filters]
Journal Article
Zielonka S, Krah S, Arras P, Lipinski B, Zimmermann J, Boje ASvea, Klausz K, Peipp M, Pekar L. Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display. Methods Mol Biol. 2023;2681:231-248.
Sahin M, Remy MM, Fallet B, Sommerstein R, Florova M, Langner A, Klausz K, Straub T, Kreutzfeldt M, Wagner I, et al. Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors. Cell Rep. 2022;38(5):110303.
Müller K, Vogiatzi F, Winterberg D, Rosner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MPauline, Brüggemann M, Cario G, et al. Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. Blood. 2022.
Derer S, Beurskens FJ, Rosner T, Peipp M, Valerius T. Complement in Antibody-Based Tumor Therapy. Crit Rev Immunol. 2014;34(3):199-214.
Derer S, Cossham M, Rosner T, Kellner C, Beurskens FJ, Schwanbeck R, Lohse S, Sina C, Peipp M, Valerius T. A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. J Immunol. 2015.
Schewe DM, Vogiatzi F, Münnich IA, Zeller T, Windisch R, Wichmann C, Müller K, Bhat H, Felix E, Mougiakakos D, et al. Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade. Hemasphere. 2024;8(2):e48.
Baumann N, Rosner T, Jansen JHMarco, Chan C, Eichholz KMarie, Klausz K, Winterberg D, Müller K, Humpe A, Burger R, et al. Enhancement of EGFR antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/SIRPα interactions. Cancer Sci. 2021.
Rosner T, Lohse S, Peipp M, Valerius T, Derer S. Epidermal Growth Factor Receptor Targeting IgG3 Triggers Complement-Mediated Lysis of Decay-Accelerating Factor Expressing Tumor Cells through the Alternative Pathway Amplification Loop. J Immunol. 2014.
Kellner C, Derer S, Klausz K, Rosskopf S, Wirt T, Rosner T, Otte A, Cappuzzello E, Peipp M. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity. Methods Mol Biol. 2018;1827:381-397.
Oberg H-H, Kellner C, Peipp M, Sebens S, Adam-Klages S, Gramatzki M, Kabelitz D, Wesch D. Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy. Front Immunol. 2014;5:643.
Khodoun MV, Morris SC, Shao W-H, Potter C, Angerman E, Kiselev A, Yarawsky AE, Herr AB, Klausz K, Otte A, et al. Suppression of IgE-mediated anaphylaxis and food allergy with monovalent anti-FcεRIα monoclonal antibodies. J Allergy Clin Immunol. 2020.
Kellner C, Lutz S, Oberg H-H, Wesch D, Otte A, Diemer KJ, Wilcken H, Bauerschlag D, Glüer C-C, Wichmann C, et al. Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen. Biol Chem. 2021.
Oberg H-H, Kellner C, Gonnermann D, Peipp M, Peters C, Sebens S, Kabelitz D, Wesch D. γδ T cell activation by bispecific antibodies. Cell Immunol. 2015.